In patients with type 1 diabetes (T1D), sodium-glucose cotransporter 2 (SGLT2) inhibitors plus glucagon receptor antagonists (GRAs) may improve glycemic control, reduce insulin use, and mitigate ...

The first meta-analysis analyzed 70,361 participants from 10 randomized trials, and found those allocated to receive an SGLT2 ...

An analysis of real-world data from a single medical center is providing insight into the effects of off-label glucagon-like peptide 1 (GLP-1) receptor agonist (RA) and sodium-glucose cotransporter-2 ...

Credit: Getty Images. Despite a warning from the FDA Adverse Event Reporting System, studies have found that SGLT2 inhibitor use is not associated with an increased risk of AKI. Using a sodium-glucose ...

Study findings indicate synergistic effects of SGLT2 inhibitors and MRAs on albuminuria. Combining a sodium-glucose cotransporter-2 (SGLT2) inhibitor and mineralocorticoid receptor antagonist (MRA) ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patients with ...

As a class, sodium–glucose transporter 2 inhibitors are novel drugs initially developed for glycemic control in patients with type 2 diabetes. [Cowie MR, et al. Nat Rev Cardiol. 2020;1a] Their primary ...

The final thesis of Professor Lim Soo's team of the Department of Endocrine Metabolism at Bundang Seoul National University Hospital was published in the world-renowned journal Nature Review (IF 40.4) ...

Case demonstrates initiation of a sodium-glucose cotransporter-2 (SGLT2) inhibitor in a patient with type 2 diabetes and heart failure. A 56-year-old man with a history of hypertension and type 2 ...

"Sodium-glucose co-transporter-2 (SGLT2) inhibitors Target Population, Competitive Landscape, and Market Forecast report" DelveInsight analysis reveals SGLT2 inhibitors market poised for significant ...